LifeSci Venture Partners focuses on investing in clinical-stage companies within the biotech, life sciences, medicine, technology, and healthcare sectors across the United States. They seek transformational business models with proof-of-concept, aiming for companies that plan to go public within 12-18 months.
Portfolio
3
Fund Size
—
Top Stage
Series C
Last 12 Mo
1
Stage Distribution
Portfolio
3 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Brainomix | Series C | $18M | Mar 2025 |
| Averto Medical Inc | Series A | $30.5M | May 2024 |
| Athira Pharma, Inc. | Series B | $85M | Jun 2020 |
Top Co-Investors
Parkwalk Advisors1 shared
Boehringer Ingelheim Venture Fund1 shared
Cormorant Asset Management1 shared
Perceptive Advisors1 shared
RTW Investments1 shared
Viking Global Investors1 shared
Franklin Templeton1 shared
Rock Springs Capital1 shared
Surveyor Capital1 shared
Logos Capital1 shared
Janus Henderson Investors1 shared
Sofinnova Partners1 shared
Avidity Partners1 shared
Last updated: 3 March 2026